Search results
Results from the WOW.Com Content Network
CRSP Market Cap data by YCharts. 3. Intensive competition. The success of CRISPR Therapeutics will depend on its ability to bring multiple new drugs to the market to support a more viable business ...
What's going on with CRISPR Therapeutics (NASDAQ: CRSP)? The company's shares have been southbound for the better part of three years. And despite major regulatory wins since late 2023, the ...
In the past three years, CRISPR Therapeutics (NASDAQ: CRSP) has made tremendous progress. It was still a clinical-stage biotech in 2021, but it now has a gene-editing therapy that is approved in ...
CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. But don't expect CRISPR to try to offload ...
On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. After all, it's been less than a year since regulators in the U.S. and E.U. approved its ...
One stock that has been struggling and that arguably should be doing a lot better these days is CRISPR Therapeutics (NASDAQ: CRSP). ... Although CRISPR did have some positive news at the beginning ...
CRISPR Therapeutics (CRSP) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.